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Acute myeloid leukaemia therapeutic innovation and clinical
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Summary
Outcomes in acute myeloid leukaemia have improved stea-
dily over the last six decades thanks to advances in disease
classification, risk stratification and the advent of new drug
and transplant therapies. Over this period the UK has made
a major contribution to this international effort, both
through its delivery of large prospective randomised trials
with integrated genomic and measurable residual disease
assessments and its pioneering role in the development of
allogeneic stem cell transplantation as a potent anti-leukae-
mic therapy.
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‘This royal throne of kings, this sceptred isle. . .
This blessed plot, this earth, this realm. . ..’:
Richard II
The UK’s contribution to the improvement of outcomes in
adults with acute myeloid leukaemia (AML) is a tribute to
the work of many clinicians and translational scientists.
However, three figures stand out in the UK’s international
contribution to advancing the treatment of AML. None more
so than Alan Burnett. Combining an exceptional ability to
identify tractable therapeutic questions and a visionary recog-
nition of the power of randomised trials in haematological
malignancies Alan’s ability to integrate large and small hospi-
tals across the UK into a cohesive trials network resulted in
the seamless delivery of a pipeline of practice informing trials
and has served as a model for other diseases. At the same
time, by making trial entry the default option in hospitals
across the length and breadth of the land, he was responsible
for the standardisation of routine care in AML to substantial
patient benefit. A common theme championed by Sir John
Bell in the HM Government Life Sciences Strategy is the
UK’s opportunity to leverage the combined strengths of its
world class science base and the internationally significant
cohorts resident within the NHS to accelerate the delivery of
clinical trials with embedded discovery medicine. There can
be no better exemplar of the UK’s potential to excel as a
uniquely effective international destination for clinical trial
delivery than the cohort of AML trials delivered by Alan,
sometimes with ruthless Glaswegian efficiency, which have
transformed treatment paradigms consequent upon the inte-
gration of disease biology and measurable residual disease
(MRD) quantitation into routine trial design.
John Goldman played a central role in the management of
myeloid leukaemias internationally and serves as an abiding
inspiration to so many colleagues fortunate enough to work
with him. John was the embodiment of the clinician scientist
combining a fascination with disease biology, specifically the
molecular pathogenesis of chronic myeloid leukaemia
(CML), coupled with a relentless spirit of therapeutic inno-
vation. Over and above his enormous contribution to the
transformation of outcomes for patients with CML, John’s
work also laid the ground for many of the recent pivotal
advances in the management of AML. His effective partner-
ship with Brian Druker in the development of imatinib
mesylate was critical to the subsequent development of tar-
geted therapies in AML. John also pioneered the use of
quantitation of BCR-ABL transcripts numbers in the assess-
ment of response to drugs and transplant; work that
informed the development of MRD strategies in AML.
Finally John played a central international role in the devel-
opment of allogeneic stem cell transplantation (allo-SCT) as
a curative therapy in myeloid malignancies and his work
underpins the central role allografting now plays in the man-
agement of high-risk AML. More than anything however, it
was John’s warmth, generosity, profoundly liberal instincts
and passionate belief in collaboration with European and
international colleagues that inspired generations of haema-
tologists. And the unforgettable ward rounds during which
the works of Shakespeare-especially his favourite play
Richard II were as much a topic of conversation as the
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relayed opinions of his dear friend and brilliant colleague
Robert Peter Gale, all the way from the unspeakably glam-
orous Los Angeles, on the management of a particularly chal-
lenging patient.
My other personal inspiration has been David Grimwade,
a brilliant, generous and innovative translational clinician,
whose creativity and spirit lit up so many meetings and dis-
cussions. None more so than our personal ritual of drinking
a bottle of Paul Draper Ridge Zinfandel over dinner on the
first evening of the American Society of Haematology meet-
ing, regardless of the time in the UK! David was an adven-
turous scientist who was fascinated by the biology of
leukaemia and had the vision to see that advances in basic
science were of immediate potential relevance to patient care.
He possessed a rare pragmatism and humility immediately
recognising that if scientific advances were to be integrated
into day to day patient management, scientists such as him-
self needed to roll their sleeves up and interact on a daily
basis with ‘coalface’ clinicians across the UK. I well remem-
ber shared summer holidays in Burgundy where in the mid-
dle of a languorous lunch David would suddenly disappear
to e-mail clinicians and research nurses with the latest MRD
data on their patients, only to return a couple of hours later
to finish the bottle! David was such a fantastic example of
how to break down the all too common barriers between the
laboratory and the clinic, and his meticulous attention to
detail, infectious spirit of enquiry, and committment to
innovation are a lasting inspiration of what can be achieved
to improve patient outcome from a genuine multidisciplinary
approach.
‘A cold coming we had of it’: The Journey of
the Magi
In 1960 when the British Society of Haematology was estab-
lished AML was an almost universally incurable disease. Hayhoe
an Whitby’s1 seminal paper reported a median survival of
4 months in adults with AML. In the 1970s and 1980s the
work of British haematologists notably Frank Hayhoe, Bar-
bara Bain, David Galton, Daniel Catovsky and David Swirsky
played a centrally important role in the development of accu-
rate morphological classification of AML, allowing repro-
ducible and accurate diagnosis and confident differentiation
from acute lymphoblastic leukaemia and other clinical enti-
ties. Subsequently, and working with American and Euro-
pean colleagues, Daniel Catovsky and David Galton played a
leading role in the development of the morphological
French-American-British (FAB) classification of AML, which
for the first time provided agreed and consistent diagnostic
criteria at the same time as demonstrating the power of
international collaboration.2 The extent to which this work
transformed the routine diagnosis and treatment of AML
should not be under-estimated and I well remember as a
Registrar at the Hammersmith Hospital in the 1980s the
hushed, almost mystical, reverence with which David Swirsky
would apply and interpret the results of Sudan Black,
myeloperoxidase and dual esterase stains on a newly diag-
nosed patient with acute leukaemia, whilst deftly sweeping
away ash that had fallen onto the microscope slide from the
ubiquitous cigarette on his lips. No burdensome Health and
Safety regulations then!
‘The fault dear Brutus is not in our stars but in
ourselves’: Julius Caesar
The next major advance in the diagnosis and management of
AML was the demonstration by David Grimwade, Tony
Goldstone and Alan Burnett that karyotypic abnormalities
were of important prognostic significance in newly diagnosed
adults treated with intensive chemotherapy.3 The Medical
Research Council (MRC) classification, as its soubriquet
became, was adopted by other international groups as a pre-
defined stratification in clinical trials and rapidly impacted
clinical practice particularly with regard to which patients
should be considered for an allograft. Subsequently the MRC
group, in studies led by Panos Kottaridis, Rosemary Gale
and David Linch, were among the first to demonstrate the
prognostic significance of fms-related tyrosine kinase 3
(FLT3) gene mutations in newly diagnosed AML; work that
transformed risk stratification of fit adults with AML and
contributed to the subsequent development of trials of FLT3
inhibitors as a therapeutic strategy.4,5 Next Eli Papaemmanuil
and Peter Campbell from the Sanger Institute at Cambridge
University, working with Hartmut Dohner and the AMLSG
German Co-operative Group, utilised next-generation
sequencing (NGS) technology to establish a novel genomi-
cally based classification of AML, with the potential to fur-
ther refine disease prognostication.6 This important work is
now being extended by Brian Huntly, Paresh Vyas and Nigel
Russell using UK National Cancer Research Institute (NCRI)
trials cohorts. In subsequent work Lynn Quek and Paresh
Vyas, working with the Birmingham Transplant group, were
amongst the first to report the ability of a NGS strategy to
predict outcome after allo-SCT in adults with AML.7
Inspired by Alan Burnett, David Grimwade and Sylvie
Freeman played a key role in the establishment of polymerase
chain reaction-based and flow cytometric MRD quantitation
to inform risk stratification and guide decision-making in
AML. David pioneered the use of serial quantitation of
promyelocytic leukaemia:retinoic acid receptor alpha (PML:
RARA) transcripts in acute promyelocytic leukaemia
(APML), as an effective strategy to both identify high-risk
patients early during their treatment course and detect early
molecular relapse permitting institution of salvage therapies.8
In a subsequent pivotal paper he extended this principle to
non-APML disease showing that serial quantitation of nucle-
ophosmin 1 (NPM1) transcripts in the peripheral blood of
adults with NPM1 + AML treated with induction
chemotherapy (IC) was able to identify patients at a high risk
of relapse; data that underpins the current practice of
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recommending an allograft rather than further chemotherapy
in these patients.9 In important complementary studies, Syl-
vie Freeman showed that immunophenotypic quantitation of
MRD permitted risk stratification in the great majority of
both younger and older adults treated with IC and was able
to use these data to further refine definitions of disease resis-
tance.10
‘To be, or not to be, that is the question’
Hamlet
It is beyond the scope of this article to exhaustively review
the results of the comprehensive programme of clinical trials
delivered by the UK AML Working Party (WP). A summary
of the results of the most recent seven trials addressing inten-
sive therapy options in a total of 16 959 patients who partici-
pated in a total of 33 249 randomisations from more than
190 hospitals in the UK, Denmark, New Zealand and Ireland
has recently been published in this Journal.11 Highlights of
recent MRC/NCRI trials included the evaluation of the bene-
fit of adjunctive gemtuzumab ozogamicin (Mylotarg) therapy
in newly diagnosed adults with AML.12 Coupled with data
from the Acute Leukemia French Association (ALFA) Group,
led by Herve Dombret, these trials demonstrated Mylotarg
improved survival in adults with good- and intermediate-risk
cytogenetics, but showed no survival benefit in patients with
an adverse risk karyotype.13,14 The NCRI trials group, having
demonstrated decreased survival in patients with a FLT3
mutation were one of the first groups to evaluate the addi-
tion of a FLT3 inhibitor to induction chemotherapy in
patients with FLT3 + AML. Although addition of lestaurtinib
to IC did not improve survival, Steve Knapper was able to
demonstrate, in a highly effective collaboration, with Mark
Levis from John Hopkins that a subgroup of patients who
achieved drug levels sufficient to inhibit FLT3 function
in vitro demonstrated improved survival.15 Working as an
effective clinical and translational team Alan Burnett, Nigel
Russell and David Grimwade also drove fundamental changes
in the management of APML. In addition to establishing the
clinical value of sequential monitoring of PML-RARA tran-
scripts as a reproducible MRD strategy, the results of the
AML17 trial played an important role in establishing all-trans
retinoic acid (ATRA) and arsenic trioxide as first-line therapy
for adults with APML.16
‘We are such stuff as dreams are made on, and
our little life is rounded with a sleep.’ The
Tempest
Most adults with newly diagnosed AML are not fit enough
for intensive treatment. The UK AML WP was a trail-blazer
in the development of randomised trials in this important
and clinically challenging patient population. The AML 14
trial, for the first time, established low dose cytosine arabi-
noside (ara C) as standard of care in older patients unfit for
IC.17 Building on the success of AML14, Alan Burnett and
Robert Hills went on to pioneer an innovative Pick-A-Win-
ner multi-arm multistage trial design, which allowed simulta-
neous randomised comparisons of promising new therapies
using low-dose ara-C as the standard arm.18 Reasoning that
a significant increase in the complete remission (CR) rate
was necessary, although not sufficient, for an agent to
improve overall survival the Pick-A-Winner model employed
a two-stage evaluation of novel agents requiring a doubling
in CR rate before extending the randomisation to look for a
survival benefit. Now led by Mike Dennis the LI-1 trial rep-
resents not only the largest prospective cohort of patients
treated with low dose ara-C, but has also proved an effective
strategy for the evaluation of novel therapies that has been
applied to other disease settings.
A notable characteristic of the portfolio of prospective
randomised trials delivered by the MRC and NCRI groups
has been their highly innovative statistical design. Brilliant
statisticians, notably Keith Wheatley and Robert Hills, have
been at the heart of the development of new trial models,
such as the use of factorial design that allows a number of
questions to be asked at different stages of the treatment
journey, platform trials in which eligibility for randomisation
is based on patient and disease including response to prior
therapy, the concept of donor-versus-no donor analysis to
evaluate the benefit of a sibling allograft and the develop-
ment of the Pick-A-Winner design in older patients.
‘If tis well done tis well t’were done quickly’
Macbeth
In the 1970s and 1980s UK transplant centres working with
the European Society for Blood and Marrow Transplantation
(EBMT) and USA colleagues pioneered the development of
allo-SCT as an effective strategy to reduce relapse in high-risk
acute leukaemia, consequent upon both the augmented anti-
tumour activity of a myeloablative conditioning (MAC) regi-
men and the genesis of a potent graft-versus-leukaemia (GVL)
effect. The challenge next lay in establishing whether a
myeloablative allograft improved overall survival in patients
with AML in CR1 transplanted using a sibling donor? The
work of Richard Grey and Keith Wheatley in developing the
concept of a donor versus no donor analysis therefore repre-
sented an important advance.19 Although likely under-estimat-
ing the benefit of an allograft, this statistical approach was
central to the demonstration in a meta-analysis co-ordinated
by Jan Cornelissen and Bob Lowenberg from the HOVON
Group, of a survival benefit in the donor group; a benefit that
was notably restricted to patients aged <35 years because of
the toxicity of a MAC regimen.20 At about this time reduced
intensity conditioning (RIC) regimens had been shown to per-
mit the extension, in principle at least, of a potentially curative
GVL effect to older patients with high-risk AML. However,
these early RIC regimens were associated with a high risk of
acute and chronic graft-versus-host disease (GVHD). Thus
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Steve Mackinnon’s development of a RIC regimen incorporat-
ing T-cell depletion utilising in vivo alemtuzumab represented
an important advance permitting allografts to be performed in
patients with high-risk AML up to the age of 75 years with
only a modest GVHD risk.21 Nigel Russell was subsequently
able to demonstrate a survival advantage of alemtuzumab-
based RIC transplants compared with chemotherapy in older
adults with AML.22 In separate studies investigators from the
NCRI group working with the EBMT were able to both rede-
fine primary refractory AML and confirm allo-SCT as the only
curative therapy in these challenging patients.23,24 Recognising
that disease relapse is the major cause of treatment failure after
a RIC allograft, the prospective examination of novel RIC regi-
mens and post-transplant maintenance strategies, has been led
by the NCRI group, in the subsequent FIGARO, COSI and
AMADEUS trials.25
‘We that are young shall never see so much
nor live so long’ King Lear
Although outcomes in AML have improved in the last
60 years, particularly in younger patients and those with speci-
fic genomically defined subtypes such as APML, the majority
of adults remain destined to die of refractory or relapsed dis-
ease. However, the investment of trillions pounds and dollars
into basic science laboratories over the last six decades, predi-
cated on the delivery of improved clinical outcomes, has at last
resulted in the development of a range of novel therapies in
both younger and older patients. Drugs such as CPX-351,
FLT3 inhibitors, isocitrate dehydrogenase 1 (IDH1) and IDH2
inhibitors and the B-cell leukaemia/lymphoma 2 (Bcl-2) inhi-
bitor venetoclax, coupled with increased accessibility to the
curative potential of transplantation promise to significantly
improve outcomes in patient subgroups where little progress
has previously been made. Coupled with the ability of both
genomics and sequential MRD analyses to guide treatment
decisions, 2020 is an important time to reappraise the trials
infrastructure required if we are to ensure that patients benefit
as rapidly as possible from the investment their parents and
grandparents have trustingly made into basic science. This will
require a radical reconfiguration of how we deliver clinical
trials so that we build trial acceleration networks that permit
the rapid assessment of an anticipated tsunami of new drug
and cellular therapies, so that their path to licensing is has-
tened. Such trials must be characterised by high levels of aca-
demic engagement and embed genomics, MRD and discovery
science as key outputs. The Contract Research Organisation
sector, which has traditionally been used by the global phar-
maceutical sector to deliver licensing trials of novel agents, is
palpably failing both the pharmaceutical sector and patients at
a time of increased genomic stratification in terms of both
speed and cost. At the same time academic co-operative
groups, which are ideally placed to deliver trials of the scale
required, struggle to obtain funding for investigator initiated
trials, particularly after the devastating impact of COVID-19
on the philanthropic sector – and, by relying on a trials infras-
tructure inherited from the 1990s, are unable to deliver trials
with the data quality and pharmacovigilance required by
licensing authorities, such as the United States Food and Drug
Administration (FDA) and European Medicines Agency
(EMA). As a result approval of novel agents is slowed, delaying
patient access to breakthrough therapies, and the opportunity
for co-operative groups to deliver label informing trials is
squandered.
It is therefore increasingly clear that if we are to serve our
patients as they deserve in coming years, the development of
a new hybrid model of trial delivery will be essential. Co-op-
erative groups, whilst retaining their independence, must
now develop the ability to deliver licensing standard clinical
trials characterised by the augmented standards of pharma-
covigilance and data quality mandated by the FDA and
EMA. The value of embedded translational studies addressing
mechanism of drug activity and resistance, which are now of
increasing importance to the regulatory authorities as
demonstrated by Paresh Vyas’s and Lynn Quek’s insightful
work on the mechanism of action of enasidenib in IDH-2
mutated AML, will create added value for this hybrid
model.26 Importantly, the income generated by these pivotal
licensing studies will create a sustainable funding stream for
the delivery of academic investigator trials whose funding is
currently under threat. Gratifyingly the UK is playing a lead-
ing role in the development of these vitally needed trail
delivery models. Building on the visionary work of Bob
Lowenberg and the Dutch-Belgian Hematology-Oncology
Co-operative Group (HOVON), the UK’s Trials Acceleration
Programme (TAP) and IMPACT networks have demon-
strated how accelerated trial delivery models can transform
patient access to novel therapies, whilst at the same time
facilitating accelerated drug approval.27 At a time of such
therapeutic promise, new and creative models of trial deliv-
ery are urgently required; we owe our patients no less.
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